Oruka Therapeutics, Inc. $ORKA Stock: Candriam S.C.A. Lowers Holdings

Key Points

• Candriam S.C.A. reduced its Oruka Therapeutics stake by 3.9% in the third quarter, selling 13,684 shares and retaining 339,032 shares valued at about $28.3 million.
• Oruka reported a quarterly loss of $0.55 per share, missing analyst expectations of a $0.51 loss. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $133.
• Company insiders sold 179,950 shares worth about $16.5 million over the past three months; insiders own 23.49% of the company.

Candriam S.C.A. trimmed its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 339,032 shares of the company's stock after selling 13,684 shares during the period. Candriam S.C.A. owned about 0.51% of Oruka Therapeutics worth $28,341,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $474,916,000. Jupiter Topco LLC purchased a new stake in shares of Oruka Therapeutics in the second quarter worth approximately $130,968,000. Remedium Capital Partners LLC boosted its position in shares of Oruka Therapeutics by 0.9% during the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company's stock valued at $76,796,000 after buying an additional 13,247 shares during the last quarter. Avidity Partners Management LP boosted its holdings in Oruka Therapeutics by 15.1% during the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company's stock worth $37,299,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Oruka Therapeutics during the second quarter worth about $33,578,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Performance

ORKA opened at $102.86 on Monday. The company has a 50 day moving average of $88.22 and a 200 day moving average of $70.57. The company has a market cap of $6.81 billion, a PE ratio of -50.67 and a beta of -0.34. Oruka Therapeutics, Inc. has a 12 month low of $25.23 and a 12 month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Research analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the sale, the insider owned 31,771 shares of the company's stock, valued at approximately $2,376,788.51. This represents a 18.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 25,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $95.60, for a total value of $2,390,000.00. Following the sale, the chief executive officer directly owned 923,128 shares in the company, valued at $88,251,036.80. This trade represents a 2.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 179,950 shares of company stock worth $16,492,680. 23.49% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on ORKA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Wall Street Zen downgraded Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. BTIG Research reiterated a "buy" rating and set a $151.00 price target on shares of Oruka Therapeutics in a research note on Monday, October 19th. Guggenheim reissued a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. Finally, Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.